EBS - Emergent BioSolutions Inc.

NYSE - NYSE Delayed Price. Currency in USD

Emergent BioSolutions Inc.

400 Professional Drive
Suite 400
Gaithersburg, MD 20879
United States
240-631-3200
http://www.emergentbiosolutions.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees1,705

Key Executives

NameTitlePayExercisedYear Born
Mr. Fuad El-HibriFounder & Exec. Chairman1.05M4.55M1958
Mr. Robert G. Kramer Sr.CEO, Pres & Director1.09MN/A1957
Mr. Richard S. LindahlExec. VP, CFO & Treasurer776.99kN/A1964
Mr. Atul SaranExec. VP of Corp. Devel., Gen. Counsel & Corp. Sec.790.98kN/A1973
Mr. Adam R. HaveyExec. VP of Bus. Operations799.32k1.33M1971
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; RSDL (Reactive Skin Decontamination Lotion Kit), a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard for intramuscular self-injection of atropine sulfate and obidoxime chloride. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for treating botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. Further, it provides NuThrax, an anthrax vaccine; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; ADENOVIRUS 4/7, a live attenuated vaccine; rVSV-Lassa, a vaccine for prevention of Lassa fever; rVSV-Marburg, a vaccine for prevention of Marburg hemorrhagic fever; rVSV-Sudan, vaccine for prevention of Sudan hemorrhagic fever; rVSV-QUAD, a vaccine for prevention of hemorrhagic fever; and rVSV-Ebola, a vaccine for prevention of Ebola hemorrhagic fever. Additionally, the company offers FLU-IGIV to treat Influenza A infection in hospitalized patients; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract manufacturing services to third-party customers. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

Emergent BioSolutions Inc.’s ISS Governance QualityScore as of July 29, 2019 is 5. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 7; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.